Kenvue Inc. $KVUE Stock Holdings Cut by Russell Investments Group Ltd.

Russell Investments Group Ltd. trimmed its stake in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 9.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,134,521 shares of the company’s stock after selling 119,204 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.06% of Kenvue worth $20,041,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Kenvue during the second quarter worth $2,882,279,000. Pentwater Capital Management LP bought a new position in shares of Kenvue in the 2nd quarter valued at $977,094,000. HBK Investments L P lifted its stake in shares of Kenvue by 33.3% in the 2nd quarter. HBK Investments L P now owns 28,000,001 shares of the company’s stock valued at $535,080,000 after acquiring an additional 7,000,000 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Kenvue by 0.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 22,270,175 shares of the company’s stock valued at $383,938,000 after acquiring an additional 196,981 shares during the last quarter. Finally, Amundi boosted its holdings in shares of Kenvue by 41.2% during the 2nd quarter. Amundi now owns 18,483,326 shares of the company’s stock valued at $353,216,000 after acquiring an additional 5,392,413 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Weiss Ratings restated a “hold (c)” rating on shares of Kenvue in a research report on Friday, September 11th. HSBC lowered their target price on Kenvue from $20.00 to $19.00 and set a “hold” rating for the company in a report on Monday, August 10th. Wall Street Zen downgraded Kenvue from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. Finally, UBS Group lifted their price target on Kenvue from $19.00 to $20.00 and gave the company a “neutral” rating in a research note on Monday, November 2nd. Ten research analysts have rated the stock with a Hold rating. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $19.29.

View Our Latest Stock Report on Kenvue

Kenvue Stock Performance

KVUE opened at $19.31 on Thursday. Kenvue Inc. has a fifty-two week low of $14.06 and a fifty-two week high of $20.13. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71. The firm has a market capitalization of $37.09 billion, a price-to-earnings ratio of 21.94, a PEG ratio of 1.77 and a beta of 0.48. The company’s 50 day moving average price is $18.51 and its two-hundred day moving average price is $18.31.

Kenvue (NYSE:KVUE – Get Free Report) last announced its quarterly earnings results on Friday, October 30th. The company reported $0.29 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.29. The firm had revenue of $3.89 billion during the quarter, compared to analysts’ expectations of $3.86 billion. Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The company’s revenue was up 3.2% on a year-over-year basis. During the same period in the prior year, the company posted $0.28 EPS. As a group, research analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 2nd. Investors of record on Monday, September 21st were paid a $0.21 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.84 annualized dividend and a dividend yield of 4.4%. Kenvue’s payout ratio is currently 95.45%.

About Kenvue

(Free Report)

Kenvue Inc. is a consumer health company that develops and sells products for everyday health and personal care. Its portfolio includes over-the-counter medicines, skin and hair care, oral care, wound care, and baby care products. Its well-known brands include Tylenol, Neutrogena, Aveeno, Listerine, Band-Aid, Johnson’s, and Zyrtec. Kenvue organizes its business around Self Care, Skin Health and Beauty, and Essential Health. The company became an independent business in 2023 after Johnson & Johnson completed the separation of its consumer health business.

Read More

Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).

Institutional Ownership by Quarter for Kenvue (NYSE:KVUE)

Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.